STOCK TITAN
  1. Home
  2. BMBIF

Bright Minds Biosciences (BMBIF) Stock Price, News & Analysis

BMBIF
Published by Stock Titan Data refreshed

What Changed

Company Description

This page collects what Stock Titan holds for BMBIF, including price data and latest news.

Stock Performance

Chart
—
-
-
-
Performance 1 year
-
Market Cap
-
Shares outstanding

Latest News

View All
—

Bright Minds Biosciences Receives a Favorable Written Opinion from the International Searching Authority for BMB-202

—

Bright Minds Biosciences to Present at the 20th International Meeting of the International Society for Serotonin Research

conferences
—

Bright Minds Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023

—

Bright Minds Biosciences Announces Receipt of Nasdaq Deficiency Letter Regarding Independent Director and Audit Committee Requirements

—

Bright Minds Biosciences Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

—

Bright Minds Biosciences Announces Resignation of Board Member

management
—

Bright Minds Biosciences Appoints Drug Development Executive Mark A. Smith M.D., Ph.D. as Chief Medical Officer

management
—

Bright Minds Biosciences Initiates Dosing in Phase I Clinical Trial of BMB-101 for Dravet Syndrome

clinical trial
—

Bright Minds Biosciences Comments on Recent Trading Activity

—

Bright Minds Biosciences Announces Changes to its Executive Leadership Team, Marking the Transition to a Development Organization

management

Bright Minds Biosciences has 10 recent news articles. Key topics include conferences, management, clinical trial. View all BMBIF news →

SEC Filings

No SEC filings available for BMBIF.